2023煙臺年中考·快訊 | 英文版：高新區博安生物創新藥全產業鏈項目 打破多項技術壁壘

　　高新區博安生物創新藥全產業鏈項目：打破多項技術壁壘

　　Boan Biotech Innovative Drug Industry Chain Project of Gaoxin (High-tech) District :

　　Break a Number of Technical Barriers

　　博安生物是綠葉集團旗下第二家上市公司，聚焦腫瘤、免疫等疾病，進行生物藥的開發、生產和商業化。項目總投資30億元，占地85畝，一期2021年4月投產，二期2024年竣工達產，預計今年產值超過十億，5年產值將突破百億。作為高新區本土孵化培育的2022年香港主板上市企業，“蝶變”之路，展現了高新區生物醫藥產業“研發-中試-產業化”的全鏈條成長規律。

　　Boan Biotech is the second listed company under Luye Pharma, which focuses on the development, production and commercialization of biological drugs for cancer, immunity and other related diseases. The total investment of the project is 3 billion yuan, covering an area of 85 acres. The first phase has been put into operation since April 2021, while the second phase will be completed in 2024, and the output value is expected to exceed 1 billion this year and will exceed 10 billion in 5 years. As a company listed on the main board of Hong Kong in 2022, its journey towards a metamorphosis shows a whole-chain growth of Gaoxin (high-tech) Distric, which follows the path of R&D, pilot test, industrialization.

　　深耕研發，培根筑基。累計研發投入超過20億，帶動企業井噴式發展，目前開發12款生物藥，2款已在國內上市、4款正在進行上市沖刺、6款進入臨床，研發速度全國第一。其中，博優倍為全球首個獲批上市的地舒單抗生物類似藥，被評為“2022年中國醫藥生物技術十大進展”。

　　With deep research and development, solid roots and foundation, the project has an accumulative investment of more than 2 billion, which drives its soaring development. Currently, it has developed 12 biological drugs with 2 have come into domestic market and 4 getting prepared. Another 6 already go into clinic trial, the research and development speed ranks top across the country. Among them, Boyoubi is the world's first disuzumab biosimilar drug that is approved to go into the market and was rated as one of the Top 10 Pharmaceutical Biotechnology Progress of China in 2022.

　　強建平臺，賦能加速。搭建三大自主創新技術平臺，其中，全人抗體轉基因小鼠技術平臺是國內首創、業內最好的小鼠平臺，通過將人的抗體基因片段植入小鼠體內，使小鼠直接產生人類抗體，藥品研發成功率提升3倍，研發周期縮短1/2。

　　A strong platform shall enable the acceleration of development. It has three independent-built innovation technology platforms , among which, the whole-human antibody transgenic mouse technology platform is the first mouse platform in China and the best within the industry. By implanting human antibody gene fragments into mice, mice can directly produce human antibodies, increasing the success rate of drug research and development by 3 times and shortening the research and development cycle by 1/2.

　　布局全球，引才聚智。在美國、日本、德國、新加坡等世界醫藥領先地區布局研發機構，建立了與全球先進技術接軌的國際化專業團隊，擁有國際高層次人才領銜的研發人員285人，碩博占比85%以上，強大的人才團隊打破多項技術壁壘，獲得國內外發明專利31項、待批專利45項，在細胞株培養方面攻克了國外“卡脖子”技術，實現國產替代；在實體瘤抗體技術方面位居全球第二、中國第一，實現從追趕者到領跑者的跨越。

　　Laying out globally shall gather talents and wisdom. By establishing R&D institutions in United States, Japan, Germany, Singapore and other pharmaceutically leading areas of the world, Boan Biotech has set up professional teams in line with world's advanced technology. With 285 high-level international R&D personnel, 85% of whom own master or doctoral degrees, this strong talent team has broken a number of technical barriers, obtained 31 domestic and foreign invention patents and another 45 pending for approval. In terms of cell strain culture, they overcome choke-point technology and replaced foreign solution with domestic substitution. In terms of solid tumor antibody technology, it ranks second in the world and first in China, achieving a leap from a pursuer to a leader.

　　博安生物已進入高速成長期，市區兩級將繼續在孵化場地、研發投入、人才獎勵、資本加持等方面全力賦能，加快推動博洛佳、度拉糖肽等10款創新藥，60余款2類及以上醫療器械獲批上市，為“創新好藥煙臺制造”金字招牌貢獻“高新”力量。

　　Boan Biotech has entered a high-speed growth period, both city and district administrations will continue to fully support the project in terms of offering incubation sites, research and development investment, talent rewards, financial aids and so on, to accelerate the promotion of 10 innovative drugs and help with more than 60 type-2 and above medical devices get approved for the market, contributing its own forces for made-in-Yantai innovative good drug.